

Ana Arance

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8567947/publications.pdf>

Version: 2024-02-01

75
papers

21,737
citations

94433

37
h-index

95266

68
g-index

79
all docs

79
docs citations

79
times ranked

22547
citing authors

#	ARTICLE	IF	CITATIONS
1	Pembrolizumab versus Ipilimumab in Advanced Melanoma. <i>New England Journal of Medicine</i> , 2015, 372, 2521-2532.	27.0	4,838
2	Nivolumab in Previously Untreated Melanoma without BRAF Mutation. <i>New England Journal of Medicine</i> , 2015, 372, 320-330.	27.0	4,795
3	Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma. <i>New England Journal of Medicine</i> , 2014, 371, 1877-1888.	27.0	1,572
4	Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. <i>Lancet</i> , The, 2015, 386, 444-451.	13.7	1,175
5	Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). <i>Lancet</i> , The, 2017, 390, 1853-1862.	13.7	1,032
6	Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. <i>Lancet Oncology</i> , The, 2019, 20, 1239-1251.	10.7	812
7	Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma. <i>New England Journal of Medicine</i> , 2022, 386, 24-34.	27.0	766
8	Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF -mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 603-615.	10.7	751
9	Clinical implications of the intrinsic molecular subtypes of breast cancer. <i>Breast</i> , 2015, 24, S26-S35.	2.2	735
10	Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study. <i>Lancet Oncology</i> , The, 2019, 20, 1083-1097.	10.7	611
11	Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2017, 18, 863-873.	10.7	561
12	Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 1315-1327.	10.7	469
13	Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 611-622.	10.7	428
14	Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 435-445.	10.7	399
15	Immune-Related Gene Expression Profiling After PD-1 Blockade in Non-Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma. <i>Cancer Research</i> , 2017, 77, 3540-3550.	0.9	327
16	Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy. <i>JAMA Oncology</i> , 2019, 5, 187.	7.1	295
17	Vemurafenib in patients with BRAFV600 mutated metastatic melanoma: an open-label, multicentre, safety study. <i>Lancet Oncology</i> , The, 2014, 15, 436-444.	10.7	242
18	Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study. <i>Lancet Oncology</i> , The, 2013, 14, 733-740.	10.7	151

#	ARTICLE	IF	CITATIONS
19	Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic BRAF-Mutant Melanoma. <i>Clinical Cancer Research</i> , 2017, 23, 5339-5348.	7.0	142
20	Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600 mutant melanoma. <i>European Journal of Cancer</i> , 2020, 126, 33-44.	2.8	130
21	Five-Year Outcomes With Nivolumab in Patients With Wild-Type BRAF Advanced Melanoma. <i>Journal of Clinical Oncology</i> , 2020, 38, 3937-3946.	1.6	119
22	Response and survival of breast cancer intrinsic subtypes following multi-agent neoadjuvant chemotherapy. <i>BMC Medicine</i> , 2015, 13, 303.	5.5	113
23	Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for BRAF V600 Mutant Unresectable or Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , 2022, 40, 1428-1438.	1.6	90
24	Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE). <i>Annals of Oncology</i> , 2019, 30, 766-773.	1.2	78
25	Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i. <i>Nature Medicine</i> , 2020, 26, 1557-1563.	30.7	78
26	Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and management. <i>European Journal of Cancer</i> , 2019, 119, 97-106.	2.8	75
27	Molecular Markers and Targets in Melanoma. <i>Cells</i> , 2021, 10, 2320.	4.1	72
28	Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma. <i>European Journal of Cancer</i> , 2015, 51, 833-840.	2.8	71
29	Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study. <i>European Journal of Cancer</i> , 2018, 91, 116-124.	2.8	69
30	O6-methylguanine formation, repair protein depletion and clinical outcome with a 4 hr schedule of temozolomide in the treatment of advanced melanoma: Results of a phase II study. <i>International Journal of Cancer</i> , 2000, 88, 469-473.	5.1	66
31	Ability to Acquire Drug Resistance Arises Early during the Tumorigenesis Process. <i>Cancer Research</i> , 2007, 67, 1130-1137.	0.9	53
32	Long-term outcomes in patients (pts) with ipilimumab (ipi)-naive advanced melanoma in the phase 3 KEYNOTE-006 study who completed pembrolizumab (pembro) treatment.. <i>Journal of Clinical Oncology</i> , 2017, 35, 9504-9504.	1.6	53
33	Randomized phase II study of cyclophosphamide, doxorubicin, and vincristine compared with single-agent carboplatin in patients with poor prognosis small cell lung carcinoma. <i>Cancer</i> , 2001, 92, 601-608.	4.1	49
34	Ixabepilone Alone or With Cetuximab as First-Line Treatment for Advanced/Metastatic Triple-Negative Breast Cancer. <i>Clinical Breast Cancer</i> , 2015, 15, 8-15.	2.4	47
35	Pembrolizumab versus ipilimumab for advanced melanoma: Final overall survival analysis of KEYNOTE-006.. <i>Journal of Clinical Oncology</i> , 2016, 34, 9504-9504.	1.6	44
36	Clinical Models to Define Response and Survival With Anti-PD-1 Antibodies Alone or Combined With Ipilimumab in Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , 2022, 40, 1068-1080.	1.6	43

#	ARTICLE	IF	CITATIONS
37	Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma. , 2020, 8, e000391.		39
38	Ipilimumab for advanced melanoma. Melanoma Research, 2014, 24, 577-583.	1.2	38
39	Association of <i>BRAF</i> V600E/K Mutation Status and Prior BRAF/MEK Inhibition With Pembrolizumab Outcomes in Advanced Melanoma. JAMA Oncology, 2020, 6, 1256.	7.1	38
40	Long-term survival from pembrolizumab (pembro) completion and pembro retreatment: Phase III KEYNOTE-006 in advanced melanoma.. Journal of Clinical Oncology, 2020, 38, 10013-10013.	1.6	23
41	Intermittent BRAF inhibition in advanced BRAF mutated melanoma results of a phase II randomized trial. Nature Communications, 2021, 12, 7008.	12.8	22
42	A randomized, open-label clinical trial of tasisulam sodium versus paclitaxel as second-line treatment in patients with metastatic melanoma. Cancer, 2014, 120, 2016-2024.	4.1	19
43	Ipilimumab after progression on anti-PD-1 treatment in advanced melanoma. Future Oncology, 2016, 12, 2683-2688.	2.4	17
44	Update on overall survival in COLUMBUS: A randomized phase III trial of encorafenib (ENCO) plus binimetinib (BINI) versus vemurafenib (VEM) or ENCO in patients with <i>BRAF</i> V600-mutant melanoma.. Journal of Clinical Oncology, 2020, 38, 10012-10012.	1.6	14
45	Health Care Resource Utilization and Associated Costs Among Metastatic Cutaneous Melanoma Patients Treated with Ipilimumab (INTUITION Study). Oncologist, 2017, 22, 951-962.	3.7	13
46	Initial Stage of Cutaneous Primary Melanoma Plays a Key Role in the Pattern and Timing of Disease Recurrence. Acta Dermato-Venereologica, 2021, 101, adv00502.	1.3	13
47	Long-term outcomes in patients with advanced melanoma who had initial stable disease with pembrolizumab in KEYNOTE-001 and KEYNOTE-006. European Journal of Cancer, 2021, 157, 391-402.	2.8	13
48	Adjuvant nivolumab for stage III/IV melanoma: evaluation of safety outcomes and association with recurrence-free survival. , 2021, 9, e003188.		12
49	COMBI-MB: A phase II study of combination dabrafenib (D) and trametinib (T) in patients (pts) with <i>BRAF</i> V600-mutant (mut) melanoma brain metastases (MBM).. Journal of Clinical Oncology, 2017, 35, 9506-9506.	1.6	10
50	Development of Cutaneous Toxicities During Selective Anti-BRAF Therapies: Preventive Role of Combination with MEK Inhibitors. Acta Dermato-Venereologica, 2017, 97, 258-260.	1.3	9
51	Avelumab expanded access program in metastatic Merkel cell carcinoma: Efficacy and safety findings from patients in Europe and the Middle East. International Journal of Cancer, 2021, 149, 1926-1934.	5.1	8
52	The anti-PD-1 antibody spartalizumab in combination with dabrafenib and trametinib in advanced <i>BRAF</i> V600-mutant melanoma: Efficacy and safety findings from parts 1 and 2 of the Phase III COMBI-i trial.. Journal of Clinical Oncology, 2020, 38, 10028-10028.	1.6	8
53	Frequency and Characteristics of Familial Melanoma in Spain: The FAM-GEM-1 Study. PLoS ONE, 2015, 10, e0124239.	2.5	8
54	Life-threatening colitis and complete response with ipilimumab in a patient with metastatic BRAF-mutant melanoma and rheumatoid arthritis. ESMO Open, 2016, 1, e000032.	4.5	7

#	ARTICLE	IF	CITATIONS
55	Pembrolizumab in a BRAF-mutant metastatic melanoma patient following a severe immune-related adverse event with ipilimumab. <i>Immunotherapy</i> , 2016, 8, 687-692.	2.0	7
56	TP53 mutation and tumoral PD-L1 expression are associated with depth of invasion in desmoplastic melanomas. <i>Annals of Translational Medicine</i> , 2020, 8, 1218-1218.	1.7	7
57	A Retrospective Analysis of Dabrafenib and/or Dabrafenib Plus Trametinib Combination in Patients with Metastatic Melanoma to Characterize Patients with Long-Term Benefit in the Individual Patient Program (DESCRIBE III). <i>Cancers</i> , 2021, 13, 2466.	3.7	7
58	Quality of life in patients with BRAF-mutant melanoma receiving the combination encorafenib plus binimetinib: Results from a multicentre, open-label, randomised, phase III study (COLUMBUS). <i>European Journal of Cancer</i> , 2021, 152, 116-128.	2.8	7
59	The anti-PD-1 antibody spartalizumab (S) in combination with dabrafenib (D) and trametinib (T) in previously untreated patients (pts) with advanced BRAF V600E-mutant melanoma: Updated efficacy and safety from parts 1 and 2 of COMBI-I.. <i>Journal of Clinical Oncology</i> , 2020, 38, 57-57.	1.6	7
60	Timeline of Adverse Events during Immune Checkpoint Inhibitors for Advanced Melanoma and Their Impacts on Survival. <i>Cancers</i> , 2022, 14, 1237.	3.7	7
61	Dabrafenib plus trametinib for compassionate use in metastatic melanoma. <i>Medicine (United States)</i> , 2017, 96, e9523.	1.0	6
62	Assessing outcomes in palliative chemotherapy. <i>Expert Opinion on Pharmacotherapy</i> , 2002, 3, 693-700.	1.8	5
63	Successful management of refractory immune-mediated enterocolitis with cyclosporine. <i>European Journal of Cancer</i> , 2020, 131, 37-39.	2.8	4
64	Real life outcome of advanced melanoma patients who discontinue pembrolizumab (PEMBRO) in the absence of disease progression.. <i>Journal of Clinical Oncology</i> , 2017, 35, 9539-9539.	1.6	4
65	Implementation of an NGS panel for clinical practice in paraffin-embedded tissue samples from locally advanced and metastatic melanoma patients. , 2020, 1, 101-108.		4
66	Safe anti-programmed cell death-1 rechallenge with antibody switching after immune-related adverse events: brief communication. <i>Immunotherapy</i> , 2021, 13, 745-752.	2.0	2
67	Tumor microenvironment (TME), longitudinal biomarker changes, and clinical outcome in patients (pts) with advanced BRAF V600E-mutant melanoma treated with first-line spartalizumab (S) + dabrafenib (D) + trametinib (T).. <i>Journal of Clinical Oncology</i> , 2019, 37, 9515-9515.	1.6	2
68	Effect of first-line spartalizumab + dabrafenib + trametinib on immunosuppressive features detected in peripheral blood and clinical outcome in patients (pts) with advanced BRAF V600E-mutant melanoma.. <i>Journal of Clinical Oncology</i> , 2020, 38, 10034-10034.	1.6	2
69	Abstract P2-13-21: Improved central nervous system outcomes in patients with early-stage HER2-positive breast cancer who receive neratinib for the recommended duration: Findings from the phase 3 ExteNET trial. <i>Cancer Research</i> , 2022, 82, P2-13-21-P2-13-21.	0.9	1
70	Report from the II Melanoma Translational Meeting of the Spanish Melanoma Group (GEM). <i>Annals of Translational Medicine</i> , 2017, 5, 390-390.	1.7	0
71	Pembrolizumab expanded access program (EAP) in Spain: clinical activity.. <i>Journal of Clinical Oncology</i> , 2016, 34, e21029-e21029.	1.6	0
72	Association of response to programmed death 1 receptor or ligand (PD1/PDL1) blockade with immune-related gene expression profiling across three cancer-types.. <i>Journal of Clinical Oncology</i> , 2016, 34, 3038-3038.	1.6	0

#	ARTICLE	IF	CITATIONS
73	Blood eosinophil counts as predictive marker in advanced melanoma patients treated with anti-PD1 therapies.. Journal of Clinical Oncology, 2017, 35, 66-66.	1.6	0
74	Infomelanoma 2020: an online digital application designed to assist health professionals for melanoma treatment. Annals of Translational Medicine, 2017, 5, 392-392.	1.7	0
75	Tumor microenvironment (TME), longitudinal biomarker changes, and clinical outcome in patients (pts) with advanced BRAF V600 mutant melanoma treated with first-line spartalizumab (S) + dabrafenib (D) + trametinib (T).. Journal of Clinical Oncology, 2020, 38, 39-39.	1.6	0